Research & Clinical Studies
The peer-reviewed studies and clinical trials that underpin the content on Akkermansia.co.uk. Each article on this site is referenced against published research — primarily PubMed-indexed trials and EFSA regulatory documents. This page gives direct access to the source material, with AI-assisted summaries for deeper exploration.
Akkermansia muciniphila gen. nov., sp. nov., a Human Intestinal Mucin-Degrading Bacterium
The foundational paper describing the discovery and characterisation of Akkermansia muciniphila as a new bacterial species. First isolated from human intestinal content at Wageningen University, Netherlands. Established its identity as a mucin-degrading strict anaerobe resident in the intestinal mucus layer and laid the foundation for two decades of subsequent research. Introduced the ATCC BAA-835 reference strain used in all subsequent clinical research.
A Purified Membrane Protein from Akkermansia muciniphila or the Pasteurized Bacterium Improves Metabolism in Obese and Diabetic Mice
Identified Amuc_1100 as the specific outer membrane protein responsible for the majority of Akkermansia's metabolic benefits. Demonstrated that pasteurised (heat-killed) Akkermansia produces equal or superior metabolic results to live bacteria, establishing the thermostability of Amuc_1100 as the mechanism. Foundational paper for the development of pasteurised Akkermansia supplements and the postbiotic concept. Established TLR2 as the receptor through which Amuc_1100 exerts its effects.
Supplementation with Akkermansia muciniphila in Overweight and Obese Human Volunteers: A Proof-of-Concept Exploratory Study
The landmark human RCT of Akkermansia muciniphila supplementation. 32 overweight insulin-resistant adults received live Akkermansia, pasteurised Akkermansia, or placebo for three months. Both active forms significantly outperformed placebo on insulin sensitivity, fasting glucose, total cholesterol, liver enzymes and circulating LPS. Pasteurised Akkermansia performed at least as well as live on all measures and produced superior body weight reduction. Established the clinical dose of 10 billion pasteurised cells per day. Supported the EU Novel Food application approved in 2021.
Gut Microbiome Influences Efficacy of PD-1-Based Immunotherapy Against Epithelial Tumors
Landmark study establishing that Akkermansia muciniphila abundance in the gut microbiome is a key differentiator between cancer patients who respond to anti-PD-1 immunotherapy and those who do not. Patients with low Akkermansia were significantly less likely to benefit from checkpoint inhibitor treatment. In germ-free mice colonised with non-responding patients' microbiomes, oral Akkermansia supplementation restored immunotherapy response. One of the most cited microbiome findings in oncology.
Intestinal Akkermansia muciniphila Predicts Clinical Response to PD-1 Blockade in Patients with Advanced Non-Small-Cell Lung Cancer
Human clinical study confirming and extending the Routy 2018 immunotherapy finding in a non-small cell lung cancer cohort. Baseline Akkermansia levels predicted immunotherapy response more accurately than PD-L1 expression — the standard clinical biomarker. Akkermansia-positive patients achieved a 28% objective response rate versus 18% in Akkermansia-negative patients. Provides the strongest human evidence for Akkermansia as a clinically actionable biomarker in oncology.
Akkermansia muciniphila and Improved Metabolic Health During a Dietary Intervention in Obesity
Human observational study examining 49 overweight adults undergoing caloric restriction. Higher baseline Akkermansia abundance predicted better metabolic outcomes from the dietary intervention, including greater improvements in fat mass, waist circumference and inflammatory markers. Akkermansia increased significantly with caloric restriction. Provided the first strong human evidence that Akkermansia levels are predictive of metabolic treatment response.
Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice
The study that established metabolic endotoxaemia as a mechanism linking gut microbiota disruption to systemic inflammation and insulin resistance. Demonstrated that LPS from gram-negative gut bacteria crosses a compromised gut barrier into systemic circulation, activating TLR4-mediated inflammatory cascades that drive metabolic syndrome. Essential context for understanding why Akkermansia's gut barrier-strengthening effects have metabolic consequences. Foundational for the field of metabolic endotoxaemia.
Cross-Talk Between Akkermansia muciniphila and Intestinal Epithelium Controls Diet-Induced Obesity
Influential early study demonstrating that Akkermansia muciniphila abundance is inversely correlated with body weight and adiposity in mice, and that Akkermansia supplementation in diet-induced obese mice significantly reduced fat mass and metabolic endotoxaemia. Showed Akkermansia's role in maintaining mucus layer thickness and gut barrier integrity. Helped establish the mechanistic link between Akkermansia, gut barrier function and metabolic disease.
Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila
Landmark review co-authored by Professor Patrice Cani and Professor Willem de Vos — two of the foremost Akkermansia researchers — making the case for Akkermansia muciniphila as a next-generation beneficial microbe. Covers the full evidence base at the time including biology, metabolic effects, immune modulation and potential therapeutic applications. Introduced the concept of "next-generation probiotics" for bacteria not found in traditional fermented foods.
Health Benefit of Vegetable/Fruit Juice-Based Diet: Role of Microbiome — Pomegranate Ellagitannins and Akkermansia
Examined the effects of pomegranate-derived ellagitannins and urolithins on the gut microbiome. Found that pomegranate consumption significantly stimulated Akkermansia muciniphila growth in vivo. Pomegranate is now the most consistently evidence-backed food for increasing Akkermansia, and this study is the primary reference for that finding. Ellagitannins are metabolised by gut bacteria into urolithins — bioactive compounds that further support gut and metabolic health.
Nutritional Polyphenols and the Gut Microbiota — Cranberry Polyphenols
Comprehensive review of dietary polyphenols and their relationship with gut microbiota composition. Provides evidence for cranberry A-type proanthocyanidins supporting Akkermansia muciniphila growth through a distinct polyphenol pathway to pomegranate ellagitannins. Documents the mechanistic framework for recommending polyphenol-rich foods to support Akkermansia abundance — complementary to but different from pomegranate.
Gut Microbiota Modulation by Green Tea Polyphenols
Review of evidence for green tea catechins — particularly EGCG — modulating gut microbiota composition. Identifies Akkermansia muciniphila among the bacteria consistently increased by green tea polyphenol consumption. Provides mechanistic context: EGCG promotes a gut environment favourable to Akkermansia while simultaneously inhibiting pathogenic species. Supports the recommendation of green tea and matcha as dietary strategies for Akkermansia support.
A Preliminary Study Examining the Binding Capacity of Akkermansia muciniphila and Desulfovibrio spp. to Colonic Mucin in Health and Ulcerative Colitis
Examined the binding capacity of Akkermansia muciniphila to colonic mucin in healthy individuals and those with ulcerative colitis. Found reduced Akkermansia binding in UC patients, contributing to evidence of diminished Akkermansia function and abundance in inflammatory bowel conditions. Preliminary study with mechanistic relevance to IBD research — suggests Akkermansia's protective role in the mucus layer is specifically impaired in UC.
Safety of Pasteurised Akkermansia muciniphila as a Novel Food Pursuant to Regulation (EU) 2015/2283
The official EFSA opinion establishing the safety of pasteurised Akkermansia muciniphila ATCC BAA-835 (MucT®) as a novel food ingredient in the EU. The assessment covered safety data review, toxicological evaluation, antibiotic resistance gene assessment, strain identity confirmation and manufacturing process safety. This regulatory approval is the basis on which Akkermansia supplements can be marketed legally in the EU. The UK FSA recognises this approval under the GB novel food transitional framework. Covers the pasteurised form only — live Akkermansia supplements do not have equivalent EU Novel Food approval.